ARTV Artiva Biotherapeutics, Inc.: institutional ownership and insider trading
78 funds reported holding $393M of Artiva Biotherapeutics, Inc. in their latest 13F filings; in Q2 2026 funds net bought $228M, with 39 new positions and 7 funds selling out; over the last 12 months insiders bought $109M and sold $2.52M on the open market.
Famous investors holding ARTV
- Andreas Halvorsen (Viking Global Investors): $25.3M, 0.1% of the portfolio
- Ken Griffin (Citadel Advisors): $5.91M, 0.0% of the portfolio
- Renaissance Technologies (Renaissance Technologies): $1.46M, 0.0% of the portfolio
- Two Sigma (Two Sigma Investments): $762K, 0.0% of the portfolio
Largest institutional holders of ARTV
- RA CAPITAL MANAGEMENT, L.P. — $174M
- VIKING GLOBAL INVESTORS LP — $25.3M
- Blackstone Inc. (BX) — $23.3M
- 5AM Venture Management, LLC — $22.8M
- VR Adviser, LLC — $19.8M
- FRANKLIN RESOURCES INC (BEN) — $19.4M
- Caligan Partners LP — $16.8M
- VANGUARD CAPITAL MANAGEMENT LLC — $9.52M
- Samsara BioCapital, LLC — $9.26M
- Blue Owl Capital Holdings LP — $8.48M
Recent ARTV insider trades
- Oct 6, 2026: Aslan Fred sold 23,463 shares ($169K)
- Oct 5, 2026: Aslan Fred sold 61,696 shares ($422K)
- Oct 5, 2026: Banerjee Subhashis sold 1,099 shares ($7.51K)
- Oct 5, 2026: Bush Jennifer sold 8,370 shares ($57.2K)
5%+ owners
- RA Capital Management, L.P.: 37.9% (Schedule 13D/A, filed Jul 23, 2026)
- GC Corp: 12.3% (Schedule 13D/A, filed May 28, 2026)
- VIKING GLOBAL INVESTORS LP: 5.4% (Schedule 13G, filed May 18, 2026)